Sino Biopharmaceutical (HKG:1177) will take an additional 5% stake in its CT Tianqing subsidiary in a deal worth 4.48 billion yuan.
The acquisition will increase Sino Biopharm's indirect stake in CT Tianqing to 65% from 60%, according to a Friday filing on the Hong Kong bourse. Completion is expected Sept. 16, subject to the satisfaction or waiver of the transaction conditions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.